

Keyword Index for Volume 103

- ¹H MRS 1297
- 4-hydroxynonenal 1263
- 5-fluorouracil (5-FU) 340, 581, 1163, 1617
- 5-year lung cancer risk 423
- A1 domain of tenascin-C 827
- ABCB1 560
- ABCG2 567
- acne 411
- acrylamide 1749
- active drug combinations 1369
- adenocarcinoma 217
- adenovirus 1822
- adjusted calcium 870
- adjuvant chemoradiotherapy 1163
- adjuvant chemotherapy 1788
- adolescent cancer 1448
- advanced solid tumours 993, 1554
- age 112, 416, 970
- aggressive fibromatosis 482
- ago2 532
- albumin 870
- ALCAM 1048
- alcohol consumption 127, 741, 747
- ALKBH2 362
- allogeneic bone marrow transplantation 1597
- aminopeptidase inhibitor 1362
- AML 275, 1292
- AMPK 1025
- anal carcinoma 1858
- anastomotic leakage 970
- androgen receptor 1001
- angiogenesis 1, 1422, 1571
- angiopoietin-2 1407
- angiotensin I-converting enzyme inhibitors 1644
- angiotensin II type-1 receptor blockers 1644
- Angiotensin-2 1698
- ANO1 715
- anthracycline 1518
- anti-androgens 1001
- antiangiogenesis 18, 52, 462, 772
- antibody–drug conjugate 676
- anticancer drugs 1815
- antineoplastic drug 239
- anxiety 1502
- Apo2L 1783
- apolipoproteins 391
- apoptosis 36, 43, 239, 256, 354, 642, 1237, 1692, 1783, 1808
- arginine 954
- arginine deiminase 954
- argininosuccinate synthetase 954
- aromatase inhibitor 291
- arsenic 1277
- arthralgia 291
- ASK1 1380
- association study 575
- AT1-R 1698
- AT2-R 1698
- ATP 656
- autoimmune conditions 112
- autophagy 1209, 1580
- avoidable deaths 1109
- axitinib 1554
- β_1 -integrin 1710
- base excision repair 1875
- basic fibroblast growth factor 370
- BCAR4 1284
- Bcl-2 668, 1710, 1808
- Beclin 1 1209
- BelCaP 12
- belinostat 12
- betulinic acid 43
- bevacizumab 772, 1407, 1524, 1529, 1536
- Bik 1808
- biliary stones 115
- biliary tract cancers 115, 469
- biomarkers 232, 701, 708, 1313, 1407, 1794, 1858
- bioreductive 201
- BMI 741, 1443, 1467
- bone microenvironment 370
- bone tumour 73
- BP-1 peptide 82
- brain cancer 1103, 1606
- BRCA2 918
- BRCA2 mutation 1192
- breaking bad news 171
- breast cancer 82, 90, 249, 291, 297, 401, 475, 524, 560, 668, 759, 772, 899, 1034, 1040, 1076, 1097, 1103, 1201, 1400, 1443, 1749, 1788, 1794, 1831, 1835
- breath 542
- Burkitt's lymphoma 265, 1736
- C35 401
- CA 19-9 tumour marker 1318
- CA-125 1657
- CaCC 715
- calcifications 1034
- cancer inequalities 1076
- cancer network 1076
- cancer prevention 1453
- cancer screening 708
- cancer stem cell 382, 439, 1692
- capecitabine 617, 845, 1524, 1680
- carbonate 1034
- carboplatin 12
- carcinogens 90
- carcinoma 1432
- carcinoma ex pleomorphic adenoma 1846
- carcinoma *in situ* 1269
- carcinoma, renal cell 796
- carcinoma, squamous cell 1462
- carrier risk estimates 1875
- case–control 411, 1729
- CD133 382
- CD147 1008
- CD166 382
- CD44 382
- CD44v3-10 1008
- CD70 676
- CD95 642
- CEBPA 275
- cell cycle 18, 239, 354
- cell growth 256
- cell lines 340
- cell motility 370, 715
- cell signalling 223
- cell-cycle arrest 1237
- cellular senescence 505
- cerebellum 1297
- cervical cancer 209, 310, 613, 939, 1773
- cervical screening 209, 939
- cetuximab 1542
- CGH 1277
- chemoradiotherapy 1349
- chemorefractory 324
- chemoresistance 73, 656, 1822
- chemosensitivity 332, 656
- chemotherapy 6, 159, 1407, 1415, 1644
- childhood cancer 136, 149, 1122, 1448, 1663
- childhood leukaemia 1122, 1128
- China 1085
- CHR-2797 1362
- chromatin 1269
- chronic disease 1742
- chronic lymphocytic leukaemia 642
- cisplatin 469, 845, 1343
- clinical skin examination 1502
- clinical trials 285, 1313
- clonal evolution 439
- CNS 1588
- cohort study 1093, 1443, 1749, 1755
- colon cancer 730, 961, 1025, 1209, 1415, 1680, 1852
- colorectal cancer 120, 159, 315, 324, 340, 382, 505, 575, 581, 747, 787, 910, 970, 975, 1356, 1407, 1453, 1496, 1536, 1627, 1755, 1765, 1875
- colorectal liver metastases 1542
- combination chemotherapy 469, 796, 993
- combined modality treatment 1524
- communication skills 171
- comorbidity 1742
- complement system 1201
- computerised assessment 1489
- copy-number variation 1277
- cost-effectiveness analysis 1773
- COX-2 975, 1263
- CP-868,596 1554
- C-reactive protein 870, 1154
- cross-talk 1001
- CRP 101, 1649
- CTL 552
- curative surgery 970
- CXCL12 1671
- CXCR4 1671
- cyclooxygenase 1182
- CYP2D6 765
- CYT997 597
- cytokines 291, 1453
- cytology 310, 939
- cytotoxicity 239, 1369
- DCE-MRI 597
- DCIS 1034
- death receptors 1380
- dendritic cells 1415, 1597
- deprivation 446
- diabetes 115, 120
- diagnostic marker 217
- dicer 532
- diet 1749, 1760
- dietary fatty acid 1182
- differentiated thyroid carcinoma 1115
- disabled-2 1716
- discriminative markers 1048
- discriminatory power 423
- disease-specific survival 899, 1831
- dissemination 1706
- distant metastasis 715
- distress screening 1489
- DNA cytometry 1432
- DNA double-strand breaks 1822
- DNA repair 36, 362, 1822
- DNA replication licensing 701
- DNP 1400
- docetaxel 332, 560, 1201, 1343, 1554
- donor lymphocyte infusion 1597
- dose finding 1529, 1815
- dose-dense 6
- doxorubicin 178
- drug resistance 607, 1139, 1369, 1671
- ductal carcinoma *in situ* 94
- DUSP 265
- dynamic contrast-enhanced magnetic resonance imaging 486
- dyslipidaemia 617
- E. coli* 975
- early breast cancer 776
- early diagnosis 223
- E-cadherin 249, 1835
- economic evaluation 315
- educational position 1109
- EGFR 510, 622, 1019, 1765
- EGFR inhibitor 347
- elastin-derived peptides 1562
- EMT 1716
- endocrine therapy 1284
- endometrial cancer 812, 889, 933
- endometrial cancer risk 127
- energy balance 1025
- enzastaurin 802
- EpCAM 382
- epidemiology 136, 933, 947, 1724, 1729, 1760
- epidermal growth factor 510
- epigenetics 265, 1269
- epirubicin 1201
- epistaxis 772
- epithelial dysplasia 1432
- epithelial to mesenchymal transition 401
- epithelions 1548
- Epstein–Barr virus (EBV) 1736
- ERBB2 1284
- ERBB3 1284
- ERBB4 1284
- ERK 1025
- ERK1/2 510
- erlotinib 622
- esophageal cancer 1085
- ethnicity 143, 1448
- EVII* 1292
- Ewing's sarcoma family of tumours 370, 1380

- excision repair cross-complementation group 1 (ERCC1) 845
 exercise 1760
 experimental animal models 61
 extracellular signal-regulated kinase 510

 family history 1502
 FAP 910
 fenretinide 1380
 FHIT 802
 figitumumab (CP-751,871) 332
 first-line treatment 1536
 flavonols 1453
 Flt-1 82
 fludarabine 642
 fluorescence *in situ* hybridisation 1335
 foetal germ cells 1269
 FOLFIRI 1536
 folic acid 1163
 follow-up 1657
 follow-up compliance 310
 food diary 747
 food frequency questionnaire 747
 formalin-fixed tissue 663, 1229
 French Polynesia 1115
 FTIR 1034
 fumarate 1400

 GalCer 524
 gastric cancer 1182, 1343
 gastrointestinal stromal tumour (GIST) 165
 GC-MS 542
 gemcitabine 52, 469, 1529, 1644
 gene expression 656, 1852
 gene expression profiling 1788
 gene methylation 820
 genetic testing 918
 genetics 685, 1502
 genomic instability 1139
 genomics 759
 genotoxicity 1263
 GGT 90
 GIST 1422
 glioblastoma 498, 827, 1606
 glioma 29
 GPS 1356
 graft vs host disease 1597
 graft vs tumour reaction 1597
 granulocyte-macrophage colony-stimulating factor 1331
 Great Britain 430

 HAART 416
 HDAC 12
 HDAC inhibitor 1680
 HDAC4 1215
 head and neck cancer 1173
 health policy 446
 hedgehog 43
 hepatocellular carcinoma 837, 954, 1215, 1617
 HER2 401, 475, 552, 663, 889, 1331, 1788
 HER2 and ER-negative breast cancer 1048
 HER-2 level amplification 1335
 heterogeneity 1139
 hI-con1 812
 HIF-1 1, 1571
 HIF1 α 1209
 high-resolution melting analysis 1627

 histone deacetylase inhibitor 1391
 histopathology 94
 HIV 265, 416
 HNSCC 715, 1245
 Hodgkin's lymphoma 1081
 Hospital Episode Statistics 143
 HPV DNA testing 939, 1773
 HRQOL 1173
 hTERT 1255
 human breast cancer xenograft 1192
 human papillomavirus 209, 310, 1510
 Hybrid Capture 2 939
 hypertriglyceridaemia 617
 hypopharyngeal squamous cell carcinoma (HSCC) 877
 hypoxia 201, 1057, 1571

 Id proteins 1237
 IF protein 82
 IGF 1479
 IGF-I 132, 1089
 IL-17 1245
 imaging 1657
 imatinib mesylate 482
 immunisation 209
 immunocytokines 827
 immunohistochemistry 899, 1831
 immunotherapy 812, 1415
in vivo 1066, 1562
 incidence 132, 143, 165, 416, 947, 1089, 1443, 1448, 1462
 Indians 143
 infants 1724
 inflammation 1356
 inflammatory breast cancer 532
 infliximab 1149
 insulin 1479
 insulin-like growth factor 132, 1089
 insulin-like growth factor type 1 receptor (IGF-IR) 332
 insulin-like growth factor-binding protein 7 1606
 intelectin 517
 interferon 1163
 interferon- α (IFN- α) 1617
 interleukin-2 827
 interleukin-6 787, 1154
 interobserver reproducibility 1057
 intrinsic subtype 249
 invasion 567, 802, 1182, 1422
 ionising radiation 186
 irinotecan 581, 993, 1325, 1524, 1529
 ITAM 401

 JNJ-26483327 987

 kallikrein 1422
 kinase mutations 165
 KIT 165
 KRAS 1019, 1627, 1765

 laryngeal cancer 186
 LDH 1209
 leucovorin 1343
 leukaemia 149, 1663, 1724, 1729
 leukaemia stem cell 439
 lipids 617
 liver cancer 741
 liver function tests 870
 liver resectability 1542
 lobular carcinoma 1097
 Luminex 1221
 lung cancer 217, 354, 423, 727, 1093, 1103, 1144, 1277, 1325, 1692, 1870

 lymph node density 613
 lymphocyte 685
 lymphoma 149, 1663
 Lynch syndrome 1840

 macrophages 629
 magnetic fields 1122, 1128
 malaria 1736
 malignant mesothelioma 629
 malnutrition 1736
 MammaPrint 1788
 MAPK 1716
 Markov Chain Monte Carlo 430
 Mcm5 701
 Mcol-A 1562
 MDM2 186
 mediation modelling 115
 medulloblastoma 1297, 1588
 melanoma 820, 1229, 1502, 1548, 1562
 menarche 1760
 mesenchymal stem cell 1692
 mesothelial cells 517
 mesothelioma 430, 517, 885
 meta-analysis 127, 1128, 1467, 1875
 metabolites 1297
 metachronous metastases 159
 metastasis 196, 201, 324, 524, 802, 861, 1008, 1066, 1182
 metastatic breast cancer 607, 765, 1331, 1518
 metastatic colorectal cancer 1524, 1529
 metastatic renal cell cancer 1154
 methylation 1846
 metronomic chemotherapy 52
 MGMT 29, 820
 MHC class I 552
 microarray 685
 microRNA 532, 877, 885, 1144
 microRNA biogenesis 1870
 microsatellite instability 1840
 migrants 143
 migration 567, 1040
 MiR-1-2 1292
 MiR-133a-1 1292
 miR-21 1617
 miR-22 1215
miR-29a/b/c family 275
miR-489 877
 miR145 256
 miRNA 567
 miRNA profiles 693
 mismatch repair deficiency 340
 MMP 1066
 mobile phones 1729
 mode of presentation 970
 molecular imaging 1606
 molecular marker 524, 1858
 molecular subtypes 1097
 monitoring 693
 monocarboxylate transporters 1008
 monoclonal antibodies 332, 1765
 mortality 430, 727
 motility 82
 mRNA 532
 MSH6 1840
 mTOR 622, 649, 1001
 mTOR inhibitor 1637
 mucocpidermoid carcinoma 510
 multidrug resistance 178, 1008
 Multiethnic Cohort 120
 multiple myeloma 1580, 1808
MUTYH 1875
 myeloid differentiation 629
 myeloid-derived suppressor cells 629

 nanoparticles 1606
 nanosensor 542
 nasal septum perforation 772
 NBS1 1822
 necrosis 1057
 nedaplatin 1325
 needle biopsy 1706
 needle track 1706
 neoadjuvant
 chemoradiotherapy 1019
 neoadjuvant chemotherapy, chronotherapy 1542
 neoadjuvant endocrine therapy 759
 neo-adjuvant therapy 297, 1794
 neoplasms 735, 1462
 neuroblastoma 1597
 neuropathy 1580
 never smokers 1277
 NGR-hTNF 837
 NLCQ-1 (NSC 709257) 201
 nomogram 1649
 non-small cell lung cancer 36, 347, 1221, 1325
 NOX4 1040
 nuclear test 1115
 nucleoside analogue 1391
 Nutlin-3 186

 O⁶-methylguanine-DNA methyltransferase 498
 oesophageal cancer 232, 552, 845, 1349
 oesophagus 735
 oestrogen receptor 475, 759
 oncogene 1144
 oral cancer 303
 oral contraceptives 1755
 oral potentially malignant disorders 303, 432
 oropharyngeal SCC or oropharyngeal cancer 1510
 osteopontin 1048, 1229
 osteosarcoma 73
 ovarian cancer 61, 656, 676, 685, 693, 1103, 1237
 ovarian cancer recurrence 1657
 ovarian cancer screening 454
 oxaliplatin 1349, 1415
 oxidative stress 90, 1808

P. acnes 411
 p38^{MAPK} 1380
 p53 186
 p70S6K 649
 paclitaxel 12, 889, 1362
 palliation 1318
 pancreatic 676
 pancreatic adenocarcinoma 391
 pancreatic cancer 52, 223, 649, 1057, 1318, 1571, 1644, 1671
 Pap smear 1773
 PARP 1588
 participation 1496
 parvin- β 852
 pathological response 297, 1335
 patient reported outcome measure 1485
 patient satisfaction questionnaire 1485
 patients' attitudes 1801
 PDGFRA 165
 pediatric cancer 1663, 1736
 pegylated liposomal doxorubicin 1518

- peptide aptamer 1237
personalised medicine 1144, 1852
PET 201
P-glycoprotein 178
pharmacodynamics 987
pharmacogenetics 765
pharmacokinetics 560, 597, 987, 993, 1548
phase I study 462, 597, 607, 987, 1362, 1637
phase Ib 1554
PHD2 1
PHD3 1571
phenotype 765
phosphatase and tensin homologue (PTEN) 1617
phospho-extracellular signal-regulated kinase 223
photodynamic therapy 362
Photofrin 362
physical activity 933
physical exam 1657
PI3K 370
PLA 663
pleural effusion 517
PLGF 82
polyethylene glycol 954
polymorphisms 560, 581, 1870
pooled analysis 1128
population 475
population-based 735, 1663
POSSUM 1356
power lines 1122
PP2A phosphatase 462
preclinical model 1192
precursor lesion 1085
predictive factors 29, 297, 482, 1562
predictive marker 1765
predictive multiscale model 486
predictive value of tests 708
premenopausal 90
pre-operative 1649
prognosis 94, 101, 613, 668, 918, 961, 1025, 1215, 1229, 1627, 1649, 1835, 1852, 1858
prognostic factors 159, 852, 1057, 1318, 1698
prognostic marker 249
prognostic model 776
programmed cell death 4 (PDCD4) 1617
progression 961
prolactin 1097
proliferation 1215
prospective study 730, 747
prostate cancer 256, 411, 462, 701, 708, 918, 1008, 1066, 1103
prostate-specific antigen 708
proteasome inhibitors 1580
protein-protein complexes 663
proteomics 101, 232, 391
PSA 701
psychosocial distress 1489
PTK6 (BRK) 663
PTPN11 877
puberty 1760
pyruvate 1400
quality of life 1318
quantitative real-time PCR 899
quercetin 642
quitting 1093
Rac1 370
RAD001 622
radiation 347, 1325
radiation-induced cancer 1115
radiation-related breast cancer 1081
radioembolisation 324
radiofrequency 1729
radiotherapy 6, 201, 1489, 1510
randomised controlled trial 310
randomised study 171
Ras mutations 505
RASSF1 802
RCC 101, 1649
RCTs 1801
reactive oxygen/nitrogen species 1263
receptor tyrosine kinase 196
receptor, epidermal growth factor 796
rechallenge 1518
rectal cancer 730, 1019, 1163
recurrence 776
recurrent neuroblastoma 1369
relapse risk 759
relative risks 423
relative survival 446
renal cell carcinoma 1149, 1255, 1698
renal insufficiency 1815
renin-angiotensin system 1644
replication error 340
reproductive history 1755
resistance 178
response to therapy 232, 1201
rhabdomyosarcoma 43
risk assessment 1788
risk factors 303, 411, 1085
risk model 423
risk predisposition 575
risk stratification 1144
RNA expression profile 73
RNA interference 354
RNAi 975
ROS 1040
RT-PCR 656
SAA 101
sagopilone 1548
salivary gland tumour 510, 1846
sapatitabine 1391
screening 303, 310, 1496, 1773
scrotum 1462
second breast cancer 1081
sedentary behaviour 933
seeding 1706
SELDI 101
selective internal radiation therapy 324
selenium deficiency 1736
self-renewal 439
sentinel node biopsy 1229
serum biomarkers 223, 391, 1221
side population cells 567, 1692
signal transduction inhibitors 1001
siltuximab 1154
single-domain antibody 1606
sirolimus 649, 796, 1637
SIRT 324
skin neoplasm 112
skin self-examination 1502
small cell lung cancer 622, 1710
smoking 120, 727, 1093
smoky coal 727
smoothened receptor 1297
SNP (single-nucleotide polymorphism) 575
socioeconomic status 136, 303, 446, 741, 1076, 1109, 1496, 1742
sodium selenate 462
soluble interleukin-6 receptor 787
sorafenib 1149, 1637
squamous cell carcinoma 217
squamous cell carcinoma of the head and neck 186
Src kinase 899, 1831
Sri Lanka 303
stroma 1040
sunitinib 196, 993
surgery 6, 285, 1510
survival 149, 475, 861, 889, 970, 1076, 1109, 1335, 1356, 1663, 1742, 1870
survival analysis 776, 1627
survival rate 1462
survivin 36
SV40 885
Switzerland 416
Syk kinase 401
synchronous metastases 159
tamoxifen 765
tamoxifen resistance 1284
targeted gene therapy 1822
targeted therapy 622
TEF 1808
tegafur/uracil 1343
telomerase activity and pathways 1255
temozolomide 29, 498, 820, 827, 1588
temsirolimus 649
testicular cancer 1269, 1467
testicular germ cell tumour 18
TGF β 1716
Th17 1245
therapeutic response 486
therapeutic target 1671
therapy 196, 239, 1479
therapy toxicity 820
thymic carcinoma 196
thymidine phosphorylase (TP) 845, 1680
thymidine synthase (TS) 354, 845, 1680
thymoma 6, 196
time-dependent variable 727
tissue microarray 961, 1710
TNFSF10 256
tobacco use 1093
tosedostat 1362
toxicity 581, 772, 1548
TP53 362
TRAIL 642, 1380, 1692, 1783
transcriptional regulation 275
transgenic mice 1297
trans-signalling 787
trastuzumab 61, 297, 1331, 1335
treatment outcome 505
treatment pathways 315
treatment response 1400
triage 939
triglycerides 617
triple-negative breast cancer 249
tumour cells 1706
tumour growth model 486
tumour heterogeneity 439, 486
tumour marker screening 693
tumour microenvironment 52, 1245
tumour suppressor 1144
tumour-infiltrating lymphocytes 1245
tylosin 178
tyrosine kinase inhibitor 18, 987, 1637
ubiquitin D 961
UGT8 524
UHRF1 217
UKCTOCS 454
unresectable 6
u-PAR 802
upper urinary tract 852
urinary cancers 852, 812, 1103
uveal melanoma 285
vaccination 1415
vaginal cytology 1657
valproate 1391
vascular endothelial growth factor receptor-2 (KDR) 18
vascular-disrupting agents 597
vascular-targeting agent 837
VEGF 1529
VEGFR inhibitor 347
venous thromboembolism 947
viral hepatitis 741
vitamin 1724
volatile biomarker 542
vorinostat 1391, 1680
WASF3 1066
wholegrain products 730
Wnt signalling 910
WT1 1255
xenograft 43, 498, 1588
Xuanwei cohort 727
YM155 36
Zoledronic acid 629